Key Highlights
- Shares fell 3.44% to USD 56.35 on relative Volume of 1.89.
- The third-quarter net loss was USD 297.1 million, or USD 1.99 per share.
- October offerings brought gross proceeds of about USD 1.15 billion.
- Cash, equivalents and investments were USD 2.3 billion at September 30.
Vaxcyte (NASDAQ:PCVX) shares traded at USD 56.35 on November 20, 2026, down 3.44%, with a relative volume at time of 1.89. The company has given no reason for the sharp decline or the heavy trading. It announced OPUS-1 trial results and completed its public offerings in October, then filed its report for the quarter ended September 30 on November 4, so those events predate the session.
Vaxcyte, Inc. is a Delaware corporation based in San Carlos, California. It is a Vaccine company that engineers vaccines against bacterial diseases through its XpressCF cell-free protein synthesis platform. Its pneumococcal conjugate vaccine candidates are VAX-31, VAX-24 and VAX-XL, which are broad-spectrum and carrier-sparing. It has no Revenue from commercial sales, relies on third-party manufacturers and reports on a calendar year.
The Third Quarter
Research and development expenses were USD 270.3 million versus USD 209.9 million, and general and administrative expenses were USD 37.9 million versus USD 32.4 million. Operating expenses and the operating loss were both USD 308.3 million, versus USD 242.4 million.
Interest income was USD 23.2 million versus USD 29.3 million, and other expense was USD 12.0 million versus other income of USD 0.29 million. The net loss was USD 297.1 million versus USD 212.8 million, or USD 1.99 per share versus USD 1.56.
Nine Months
Research and development expenses were USD 851.0 million versus USD 552.2 million, and general and administrative expenses were USD 105.9 million versus USD 97.1 million. The net loss was USD 902.0 million versus USD 520.1 million, or USD 6.25 per share versus USD 3.83. Operating Activities used USD 737.2 million versus USD 430.7 million.
Balance Sheet and Liquidity
Cash was USD 125.5 million versus USD 174.0 million at December 31, 2025. Short-term investments were USD 1.17 billion versus USD 1.39 billion, and Long-Term Investments were USD 972.2 million versus USD 881.7 million. Total Assets were USD 2.99 billion versus USD 3.00 billion, and Equity was USD 2.49 billion versus USD 2.69 billion.
Cash, equivalents and investments totaled USD 2.3 billion, against an accumulated Deficit of USD 3.1 billion. The company believes this is enough to fund operating and Capital needs for at least 12 months, and it expects expenses to stay high.
October Public Offerings
In October Vaxcyte completed concurrent underwritten offerings of 8,584,375 common shares at USD 64.00 each, pre-funded warrants for 400,000 shares at USD 63.999 each and USD 575 million of 1.50% convertible senior notes due 2032. The offerings included full exercise of Options for up to 1,171,875 more shares and up to USD 75 million more notes. Net proceeds were about USD 1.1 billion, and the company is still assessing the accounting effects.
VAX-31 OPUS-1 Results and Pipeline
In October the company announced topline results from OPUS-1, a randomized, double-blind, active-controlled Phase 3 trial of VAX-31 in pneumococcal-naive U.S. adults aged 50 and older (n=3,572), with a separate cohort aged 18 to 49 (n=475). It said VAX-31 met all prespecified primary endpoints across age groups against PCV20 and PCV21.
It expects OPUS-2 and OPUS-3 safety, tolerability and immunogenicity data in the first half of 2027 and is planning a Manufacturing consistency study as the final Phase 3 study before a Biologics License Application. The FDA has granted Breakthrough Therapy Designation for VAX-31 in adults.
What to Watch Next for Vaxcyte
The company has given no reason for the November 20 decline, and its results, trial data and offerings came earlier. The reported record shows a wider loss, rising research spending and a large cash and Investment base. The first half of 2027 data readouts are the next dated items.






Please wait processing your request...